Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars

ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, provided insight on potential career paths awaiting biomedical researchers.

Colman McCarthy to Receive 2010 EL-HIBRI Peace Education Prize

August  17,  2010  — The El-Hibri Charitable Foundation announced today that prominent peace educator, nationally renowned columnist and accomplished author Colman McCarthy has been selected as the recipient of the  2010 El-Hibri Peace Education Prize. The Prize, which carries a monetary award of  $15,000, is given annually by the foundation to honor an individual or organization that has made a significant contribution to the field of peace education.

Emergent BioSolutions to Acquire Trubion Pharmaceuticals

  • Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
  • Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
  • Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
  • Emergent reaffirms 2010 guidance for revenues and net income

ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –

Emergent Revises Upward 2010 Financial Forecast

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million

Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax

ROCKVILLE, Md., Jul 14, 2010

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax(R) (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company’s large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

The El-Hibri Foundation Launches Website

The El-Hibri Foundation is a nonprofit organization with the goal of fostering dialogue between various religions and encouraging nonviolent solutions to global challenges affecting humankind.  The Foundation has a new website at www.elhibrifoundation.org.